MyFinsight
Home
Blog
About
Maturities and sales of
marketable securities
$97,456K
(-33.64%↓ Y/Y)
Proceeds from issuance of
common stock upon stock...
$2,955K
(1995.74%↑ Y/Y)
Net cash (used in)
provided by investing...
$14,280K
(-81.76%↓ Y/Y)
Net cash provided by
financing activities
$2,955K
(-95.91%↓ Y/Y)
Canceled cashflow
$83,176K
Net (decrease)
increase in cash, cash...
-$60,036K
(-303.98%↓ Y/Y)
Canceled cashflow
$17,235K
Stock-based compensation
expense
$17,107K
(-13.27%↓ Y/Y)
Accrued expenses and
other current...
$7,617K
(355.69%↑ Y/Y)
Depreciation and
amortization expense
$741K
(-42.78%↓ Y/Y)
Amortization of operating
leases, right-of-use...
$628K
(-37.20%↓ Y/Y)
Prepaid expenses and
other current assets
-$297K
(86.71%↑ Y/Y)
Amortization of debt discount
and issuance costs
$284K
(350.79%↑ Y/Y)
Other liabilities
$28K
(211.11%↑ Y/Y)
Other assets
-$1K
Purchases of marketable
securities
$82,806K
(21.98%↑ Y/Y)
Purchases of property and
equipment
$370K
(-45.43%↓ Y/Y)
Net cash used in
operating activities
-$77,271K
(36.17%↑ Y/Y)
Canceled cashflow
$26,703K
Net loss
-$96,405K
(33.75%↑ Y/Y)
Accounts payable
-$6,256K
(-235.65%↓ Y/Y)
Net amortization
(accretion) of premiums...
$961K
(30.04%↑ Y/Y)
Operating lease liability
-$351K
(53.69%↑ Y/Y)
Loss on fixed asset
disposal
$1K
Back
Back
Cash Flow
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)
source: myfinsight.com